Despite the favorable prognosis of patients with acute myeloid leukemia (AML) with t(8;21)(q22;q22) translocation, relapses still occur in about 30% of the cases but no initial factors can strongly predict the risk of relapse. Several recent studies suggest that monitoring minimal residual disease (MRD) may identify patients at risk of relapse. We prospectively monitored AML1-ETO rearrangement by real-time quantitative PCR (RQ-PCR) in 21 patients uniformly treated in our center. Blood (PB) and bone marrow (BM) samples were collected during and after therapy. At diagnosis, levels of AML1-ETO transcript showed large variations and there was a trend for a higher relapse rate in patients with high pretreatment expression levels (P ¼ 0.065). After induction therapy, absolute transcript levels (below 10 À3 , compared to Kasumi cell line), or a greater than 3 log decrease by comparison to diagnosis levels, were significant predictors of the absence of relapse (P ¼ 0.02 and P ¼ 0.02, respectively). MRD levels after consolidation therapy were also significant indicators of relapse (P ¼ 10
Introduction
The t(8;21)(q22;q22) translocation, observed in about 10% of acute myeloid leukemia (AML), fuses the AML1 (RUNX1) gene located on chromosome 21 to the ETO (MTG8) gene located on chromosome 8, 1, 2 and is generally associated with favorable prognosis, 3 especially when patients are treated with high-dose cytarabine (HDAC) consolidation chemotherapy (CT). 4 However, relapses still occur in about 30% of the cases. Initial features such as a high initial white blood cell count (WBC), WBC index, CD56 expression, del (9q) in addition to t(8;21) or extramedullary disease have been associated with an increased risk of relapse. [5] [6] [7] [8] [9] We previously reported that with a qualitative RT-PCR method, a good correlation was found between rapid negativation of PCR results during treatment and absence of subsequent relapse. 10 Several studies strongly suggest that quantitative PCR (RQ-PCR) methods of minimal residual disease (MRD) detection might improve the predictive results of qualitative PCR techniques in acute leukemia. [11] [12] [13] Recently, one study reported that the quantification of AML1-ETO fusion transcript at diagnosis with a quantitative real-time PCR method could identify patients at high risk of relapse. 14 We sequentially monitored AML1-ETO rearrangement by RQ-PCR in 21 patients uniformly treated in our center, in order to assess the prognostic value of this technique.
Patients and methods

Patients and samples
A total of 21 consecutive AML patients with t(8;21), diagnosed at the University Hospital of Lille between 1994 and 2001, were analyzed (Table 1 ). All patients were included in the same therapeutic protocol (see below) and achieved hematological complete remission (CR). Blood (PB) and bone marrow (BM) samples were collected at diagnosis, after induction treatment (at CR achievement), after intensive consolidation therapy and every 3-6 months thereafter in the 21 cases (with the exception of three cases where samples after induction treatment were missing). A total of 247 samples were analyzed. For comparison of PB and BM samples, 27 paired PB and BM samples were analyzed.
Treatment
Induction treatment consisted of daunorubicin 80 mg/m 2 /day for 3 days and AraC 500 mg/m 2 /day as continuous infusion for 3 days, followed on days 8 and 9 by mitoxantrone 12 mg/m 2 /day for 2 days and AraC 500 mg/m 2 /12-h as 3-h intravenous bolus infusion on days 8-10. 15 After CR achievement, patients received a moderate consolidation course with mitoxantrone 12 mg/m 2 /day for 1 day and AraC 120 mg/m 2 /day for 5 days ((1 þ 5) course) followed by an intensive consolidation course with idarubicine 12 mg/m 2 /day for 3 days and AraC 2000 mg/m 2 /12-h as 3-h intravenous bolus infusion for 6 days (24 g/m 2 ) in 20 cases, and allogeneic SCT with a matched related donor in one case.
Techniques
Kasumi cell line, an AML1-ETO-positive cell line, served as the positive control. 16 Cells were grown in RPMI medium with 10% fetal calf serum. To compare AML1-ETO expression in patient samples and Kasumi, different quantities of Kasumi were prepared as follows: 10 5 , 10 4 , 10 3 , 10 2 for RNA extraction. White cells from patients were isolated from 10 to 20 ml PB or 1-3 ml BM by treatment with Plasmagel s (Fresenius Kabi, France). Dry aliquots of 10 6 -10 7 cells were made; total RNA was extracted with TriZol (Gibco BRL, Invitrogen, Carlsbad, CA, USA) and, after precipitation, dissolved in 19.5 ml of H 2 O þ 0.5 ml of RNAase inhibitors. Dry cells aliquots and RNA were stored at À801C. RT-PCR was performed on 1 mg of total RNA, according to Biomed1 recommendations. 17 The synthesized cDNA were stored at À201C.
RQ-PCR was performed following the 'Europe Against Cancer (EAC) Program' recommendations for the AML1-ETO fusion transcript, 18 based on TaqMan technology, on an ABI PRISM 7700 Sequence detector (Perkin-Elmer/Applied Biosystems). Quantification of AML1-ETO fusion transcript was standardized according to the expression of the housekeeping gene TBP (TATA box binding protein), a housekeeping gene giving similar results to those of ABL gene in our hands (data not shown). Results were expressed in DC t , according to RQ-PCR standard curve established with the serial dilutions of the Kasumi cell line. All samples were analyzed in duplicate. The primers and probes were as follows:
A constant level of sensitivity (10 À6 ) could be achieved with 1 mg of total RNA in nearly all cases, as verified by the dilution assay performed simultaneously to triplicate PCR amplification of each sample. Otherwise, sample examination was not validated. For patients in prolonged continuous CR, the initial RNA quantity was also increased to 2 mg to make sure that a negative examination was not caused by insufficient target RNA.
Statistical analysis
Statistical analysis was made at the reference date of 1 January 2004. Relapse-free survival (RFS) and overall survival (OS) were calculated according to the method of Kaplan and Meier, from the date of CR to relapse or death in CR, and from the day of first diagnosis to the day of death or last follow-up, respectively. Comparisons regarding RFS and OS were performed with the log-rank test. The Pearson w 2 statistic and Student t-test were used to test for differences in distribution of dichotomous variables and in the mean values of continuous distributions. The normalized expression ratios at diagnosis were correlated to event-free survival (EFS) and OS using Cox regression analysis with the initial expression ratio as a covariate and by the Spearman rank correlation.
Results
Initial characteristics of the 21 patients are summarized in Table 1 . Six (27%) patients relapsed after 11-38 months (median, 15 months) and four of them subsequently died. The median follow-up was 38 months (range 6-115 þ months). No initial clinical or hematological characteristic including age, high initial white blood cell count (WBC) or WBC index was predictive of relapse (data not shown). Regarding chromosomal abnormalities in addition to t(8;21), no prognostic impact was observed for trisomy 8 (P ¼ 0.52, Fisher exact test) nor for del(9q), but there was a trend for poorer prognosis when del(9q) was present (P ¼ 0.07, Fisher exact test). Minimal residual analysis curves of the 21 patients are summarized in Figure 1 .
At diagnosis, levels of AML1-ETO fusion transcript showed large variations, ranging from 0.23 to 31.3 (median 0.75) compared to Kasumi cell line. There was a trend for a higher relapse rate in patients with high pretreatment expression levels of AML1-ETO transcript (P ¼ 0.065). Samples after induction treatment (at CR achievement) were available in 18 of the 21 patients. Both absolute and relative decreases in fusion AML1-ETO transcript level were analyzed during follow-up. Only one of the 10 patients with a transcript level o10
À3 after induction treatment relapsed as compared to five of the eight patients with a transcript level 410 À3 (P ¼ 0.02) (Figure 2 ). In addition, only two of the 12 patients with 43 log decrease of the AML1-ETO fusion transcript (by comparison with diagnosis level) relapsed, as compared to four of the six patients with o3 log decrease (P ¼ 0.01) (Figure 2 ).
After consolidation therapy, a threshold at 10 À5 was chosen in order to avoid fluctuations of the results that can be found at limits of the level of sensitivity (10 À6 ). Five of the six patients ) ( Figure 3 ). We finally compared RQ-PCR analysis in BM and PB samples in 27 paired PB and BM samples collected simultaneously. Sensitivity in PB and BM for detecting AML1-ETO fusion transcript was similar (10 À6 ) except in one case (negative BM testing and positive PB testing in one patient with granulocytic sarcoma). No patients with at least two successive negative blood examinations relapsed after CR1 achievement. A strong correlation between BM and PB levels was found (R 2 ¼ 0.95) (Figure 4) .
Discussion
With the possible exception of WBC or WBC index at diagnosis, no initial factors can strongly predict the risk of relapse in AML with t(8;21). 9 Thus, MRD detection by quantitative RT-PCR may 
Figure 3
Kaplan-Meier plots for relapse-free survival according to MRD decrease after consolidation treatment. RFS according to MRD level after consolidation treatment. MRD level after consolidation treatment is a strong prognostic factor: 5/6 patients with an MRD 410 À5 relapsed compared to 1/15 patients with MRD 410 À5 after consolidation treatment.
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Prognostic value of RQ-PCR in AML
H Leroy et al be of great interest to predict outcome. However, contrary to acute promyelocytic leukemia (APL) 19 and acute lymphoblastic leukemia (ALL), 20 many papers have shown that neither qualitative nor semiquantitative MRD detection in t(8;21) was significantly correlated with clinical outcome. Indeed, with the exception of our previous study, 10 most studies using various semiquantitative techniques reported that the detection of the AML1-ETO fusion transcript was a common finding in longterm CR, [21] [22] [23] even after allogeneic SCT. 24 However, recently, several studies strongly suggested that RQ-RT-PCR might be a more valuable technique to predict relapse in AML with core binding factor (CBF) rearrangement in general or in t(8;21) AML. 13, 14, [25] [26] [27] In those studies, critical thresholds of MRD levels, which could distinguish between patients at risk of relapse and those in continuous CR, were identified.
In the present study, no pretreatment characteristics were predictive of the outcome, possibly due to the relatively low number of patients. As in previously published studies, 14, 25 no presenting features were correlated with the level of AML1-ETO at diagnosis. A recently published study 14 found that the quantification of AML1-ETO fusion transcript at diagnosis by quantitative real-time PCR method was predictive of treatment failure. We made similar findings, although with borderline significance (P ¼ 0.065). Our study also shows that early response to treatment assessed by RQ-RT-PCR may have a major prognostic impact. After induction therapy, absolute transcript levels (below10
À3
) or a greater than 3 log decrease by comparison to diagnosis levels were significant predictors of the absence of relapse. In a recent series, 25 less than 2 log decrease in MRD between diagnosis and CR achievement was predictive of relapse. As in childhood ALL, 20, 28 a rapid reduction of the tumor burden was associated with significantly better outcome and only two patients in continuous CR had a slow decrease rate of MRD.
MRD levels after consolidation therapy, as in AML with inv (16) and APL, 14 also seemed to be significant indicators of relapse. Indeed, only one of 15 patients with a transcript levels below 10 À5 after consolidation relapsed, as compared to five of the six patients with higher levels. Persistence of MRD in patients in continuous CR was not associated with subsequent risk of relapse provided the level of MRD remained low (o10 À5 ). Finally, our results suggest that PB samples may be used adequately to estimate the level of MRD by this technique 29 (contrary to our previous study with semiquantitative technique 10 ) and might greatly improve MRD monitoring. We had previously shown the prognostic importance of MRD detection in AML with t(8;21), using qualitative one round or nested PCR techniques. 10 Quantitative RT-PCR allows even more refined prognostic analysis in this AML subtype and should be useful for treatment monitoring in everyday practice. Owing to the relatively small number of patients analyzed here, larger multicenter studies should be made to confirm our findings.
